To study the cost variation analysis of oral H2 receptor blockers available in different brands in Indian pharmaceutical market

Hansraj Kumar, Uma Shankar Prasad Keshri, Rajeev Kumar, Manju Gari, Akash Chandra


Background: Aim of the study was to study percentage price variations among different brands of the commonly prescribed H2 receptor blockers.

Methods: The maximum and minimum price of each brand of the drug in INR was noted by using CIMS January to April 2018 edition, Drug Today April to June 2018 Vol-1. The price ratio and the percentage price variation for individual drug brands was calculated. The price of 10 tablets/capsules were calculated. At last the price ratio and percentage price variation of various brands were compared.

Results: Percentage variation in price for H2 receptor blockers marketed in India was found to be tablet cimetidine 200mg:81.89, tablet cimetidine 400mg:91.27, tablet ranitidine 150mg:295.64, tablet ranitidine 300mg:123.19, tablet famotidine 20mg:939.62, tablet famotidine 40mg:1110.09, tablet roxatidine 75mg:38.65, tablet roxatidine 150mg:21.85.

Conclusions: H2 receptor blocker is the most common drug prescribed for prolonged period in case of gastritis, Gastro-Esophageal Reflux Disease (GERD), peptic ulcer. If a costly brand is prescribed, the patients have to pay more money unnecessarily for their treatment. The doctors prescribing these drugs should be aware of these variations in price to reduce the price of drug therapy.


Gastritis, GERD, Percentage price variation, Price ratio

Full Text:



Panula P, Chazot PL, Cowart M, Gutzmer R, Leurs R, Liu WL, et al. International union of basic and clinical pharmacology. XCVIII. Histamine receptors. Pharmacological reviews. 2015 Jul 1;67(3):601-55. (PMID 26084539).

Sir James W. Black - Biographical. Retrieved 7 April 2015.

Rossi S (Ed.). Australian Medicines Handbook 2005. Adelaide: Australian Medicines Handbook. ISBN 0-9578521-9-3; 2005.

Humphries TJ, Merritt GJ. drug interactions with agents used to treat acid-related diseases. Alimentary Pharmacol Therapeutics. 1999 Aug;13:18-26. (PMID 10491725).

Ahuja J, Gupta M, Gupta AK, Kohli K. Pharmacoeconomics: Natl Med J India. 2004;17:80-3.

Sanchez LS. Pharmacoeconomics: Principles, methods and applications. In: Dipiro JT, Talbert RL, Yee GC Matzke GR, Wells BG, Possy ML, Eds. Pharmacotherapy: A pathophysiological approach. 7th Ed, Mc Graw Hill; New York; 2008:1-2.

Das SC, Mandal M, Mandal SC. A critical study on a vailability and price variation between different brands: impact on access to medicine. Indian J Pharm Sci. 2007;69(1):160-3.

Chawan VS, Gawand KV, Badwane SV. Cost analysis of oral hypolipidemic agents available in India. Int J Basic Pharmacol. 2014:3:954-7.

Thomas M. Rational drug use and essential drug concept. In: Parthasarthi G, Nyfort Hasen K, editors. A Textbook of Clinical Pharmacy Practice. Ist Ed. Himayatnagar, Hyderabad: Orient Longman: 2004:723.

Creese A, Kotwani A, Kutzin J, Pillay A. Evaluating pharmaceuticals for Health policy in low and middle -income country settings. In: Free mantle N, Hill S, eds. Evaluating pharmaceuticals for Health policy and reimbursement. Massachusetts, USA: Blackwell Publication; (in collaboration with WHO Geneva); 2004:227-243.

Mahal A, Karan A, Engelgau M. The Economic Implications of Non-communicable Disease for India. Washington, DC: World Bank. 2010. Available at: Implications of NCD for in dia.pdf.

Rataboli PV, Garg A. Confusing brand names: nightmare of medical profession. J Postgrad Med. 2005;51:13-6.

Drug cost control. Order, 2013. Government of India. Available at:

Vieira JL, Portal VL, Moriguchi EH. How much do we pay for a benefit? A descriptive cost analysis of the use of statins: The need for a national cost-effectiveness analysis. Arq Bras Cardiol. 2001;76(5):409-18.

Kumar L, Dinkar JK, Mohan L, Dikshit H. Cost variation analysis of antimalarial drugs available in India. Int J Res Med Sci. 2017;5:4051-4.